Literature DB >> 1582002

Xanthine derivative HWA 138 attenuates hemodynamic and oxygen uptake dysfunction secondary to severe endotoxin shock in sheep.

P Masouyé1, K Gunning, J F Pittet, P M Suter, D R Morel.   

Abstract

Continuous E. coli endotoxin infusion in five awake sheep produced hypodynamic shock characterized by decreased cardiac output, increased pulmonary vascular resistance (PVR), leukopenia, high plasma levels of lactate, thromboxane B2 (TXB2) and 6-keto-prostaglandin F1 alpha (6-k-PGF1 alpha), and a pathological oxygen delivery-consumption relationship, i.e., a dependence of oxygen consumption on oxygen delivery, leading to death within 8-9 hr. Pretreatment with the xanthine derivative HWA 138 in six sheep prevented the endotoxin-induced fall in cardiac output and oxygen delivery, attenuated the increase in PVR and plasma 6-k-PGF1 alpha, and prolonged survival to 13-19 hr in five of the six sheep. The xanthine derivative had no effect on endotoxin-induced leukopenia, nor on the increase of plasma lactate and TXB2 levels. Although in the HWA 138 treated animals oxygen consumption increased significantly (by 59 +/- 17% at 8 hr), this increase was only transient, and at a level that was most probably insufficient to meet the increased metabolic requirements of this model. We conclude that pretreatment with HWA 138 attenuates endotoxin-induced hemodynamic and oxygen uptake disturbances and prolongs survival in this animal model of severe endotoxin shock.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582002

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  2 in total

1.  Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis.

Authors:  R Lauterbach; M Zembala
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

2.  The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial.

Authors: 
Journal:  BMC Pregnancy Childbirth       Date:  2008-12-08       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.